Andrew Joseph , 2025-10-20 14:48:00
BERLIN — In June, Amgen reported that an experimental drug had hit the main goal of a gastric cancer study, improving overall survival in “a statistically significant and clinically meaningful” way. It said it would provide more detailed results from the interim analysis later on.
Then the situation took an unusual turn.
Last month, the company disclosed that a follow-up analysis showed that the survival benefit of the drug, called bemarituzumab, had shrunk, leading to questions about why. There were also concerns about possible safety issues, including known eye-related side effects.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
